Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma

Peter Borchmann(University of Cologne), Andreas Engert(University Hospital Cologne), A. Bernareggi, Jan Oliver Staak, Kai Hübel(University Hospital Cologne), Peter Staib(Sankt-Antonius-Hospital Eschweiler), R. Schnell(University of Cologne), Volker Diehl(University of Cologne), R Knippertz, Gabriella Camboni, Alexander Schulz

Annals of Oncology

May 1, 2001

10.1023/a:1011139016294

Cited by 52

Related Papers

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

|Blood|2003|717

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

|JAMA|2011|320

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

|Journal of Clinical Oncology|2012|261

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

|Journal of Clinical Oncology|2017|248

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

|Journal of Clinical Oncology|2013|212